American Heart Journal
Volume 146, Issue 2 , Pages 227-233 , August 2003

Role of lipid and lipoprotein profiles in risk assessment and therapy

  • Christie M Ballantyne, MD

      Affiliations

    • Section of Atherosclerosis, Department of Medicine, Baylor College of Medicine, Houston, Tex, USA
    • Corresponding Author InformationReprint requests: Christie M. Ballantyne, MD, Baylor College of Medicine, 6565 Fannin St, M.S. A-601, Houston, TX 77030, USA.
    • ,
  • Ron C Hoogeveen, PhD

      Affiliations

    • Section of Atherosclerosis, Department of Medicine, Baylor College of Medicine, Houston, Tex, USA

Received 18 April 2002 ,Accepted 28 August 2002.

References 

  1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults . Executive Summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  2. Neaton JD, Wentworth D  Multiple Risk Factor Interventional Trial Research Group . Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease (overall findings and differences by age for 316 099 white men). Arch Intern Med. 1992;152:56–64
  3. Verschuren WM, Jacobs DR, Bloemberg BP, et al.  Serum total cholesterol and long-term coronary heart disease mortality in different cultures (twenty-five year follow-up of the Seven Countries Study). JAMA. 1995;274:131–136
  4. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease (the Framingham Heart Study). Can J Cardiol. 1988;4(A Suppl):5–10A
  5. Lipid Research Clinics Program . The Lipid Research Clinics Coronary Primary Prevention Trial results, I (reduction in incidence of coronary heart disease). JAMA. 1984;251:351–364
  6. Buchwald H, Varco RL, Matts JP, et al.  Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia (report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)). N Engl J Med. 1990;323:946–955
  7. Scandinavian Simvastatin Survival Study Group . Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease (the Scandinavian Simvastatin Survival Study (4S)). Lancet. 1994;344:1383–1389
  8. Shepherd J, Cobbe SM, Ford I, et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301–1307
  9. Sacks FM, Pfeffer MA, Moye LA, et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–1009
  10. Downs JR, Clearfield M, Weis S, et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels (results of AFCAPS/TexCAPS). JAMA. 1998;279:1615–1622
  11. Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group . Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–1357
  12. Heart Protection Study Collaborative Group . MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals (a randomised placebo-controlled trial). Lancet. 2002;360:7–22
  13. Gordon T, Castelli WP, Hjortland MC, et al.  High density lipoprotein as a protective factor against coronary heart disease (the Framingham Study). Am J Med. 1977;62:707–714
  14. Jacobs DR, Mebane IL, Bangdiwala SI, et al.  High-density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women (the follow-up study of the Lipid Research Clinics Prevalence Study). Am J Epidemiol. 1990;131:32–47
  15. St-Pierre AC, Ruel IL, Cantin B, et al.  Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation. 2001;104:2295–2299
  16. Assmann G. Pro and con (high-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management). Am J Cardiol. 2001;87(Suppl):2–7B
  17. Grundy SM, Bazzarre T, Cleeman J, et al.  Prevention Conference V. Beyond secondary prevention (identifying the high-risk patient for primary prevention: medical office assessment). Circulation. 2000;101:E3–11
  18. Gotto AM, Whitney E, Stein EA, et al.  Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000;101:477–484
  19. Stein E. Laboratory surrogates for anti-atherosclerotic drug development. Am J Cardiol. 2001;87(Suppl):21–26A
  20. Lamarche B, Tchernof A, Mauriege P, et al.  Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA. 1998;279:1955–1961
  21. Sharrett AR, Ballantyne CM, Coady SA, et al.  Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions (the Atherosclerosis Risk in Communities (ARIC) Study). Circulation. 2001;104:1108–1113
  22. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol. 1992;70:733–737
  23. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol. 1998;81:18–25B
  24. Gordon DJ, Probstfield JL, Garrison RJ, et al.  High-density lipoprotein cholesterol and cardiovascular disease (four prospective American studies). Circulation. 1989;79:8–15
  25. Stampfer MJ, Sacks FM, Salvini S, et al.  A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1991;325:373–381
  26. Krauss RM. Dense low density lipoproteins and coronary artery disease. Am J Cardiol. 1995;75:53–57B
  27. Castelli WP, Anderson K, Wilson PW, et al.  Lipids and risk of coronary heart disease (the Framingham Study). Ann Epidemiol. 1992;2:23–28
  28. Assmann G, Schulte H. Role of triglycerides in coronary artery disease (lessons from the Prospective Cardiovascular Munster Study). Am J Cardiol. 1992;70:10–13H
  29. Manninen V, Tenkanen L, Koskinen P, et al.  Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study (implications for treatment). Circulation. 1992;85:37–45
  30. BIP Study Group . Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease (the Bezafibrate Infarction Prevention (BIP) study). Circulation. 2000;102:21–27
  31. Ballantyne CM, Olsson AG, Cook TJ, et al.  Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation. 2001;104:3046–3051
  32. Ballantyne CM, Andrews TC, Hsia JA, et al.  Correlation of non–high-density lipoprotein cholesterol with apolipoprotein B (effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non–high-density lipoprotein cholesterol levels). Am J Cardiol. 2001;88:265–269
  33. Cui Y, Blumenthal RS, Flaws JA, et al.  Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med. 2001;161:1413–1419
  34. Castelli WP, Abbott RD, McNamara PM. Summary estimates of cholesterol used to predict coronary heart disease. Circulation. 1983;67:730–734
  35. Gaziano JM, Hennekens CH, O’Donnell CJ, et al.  Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation. 1997;96:2520–2525
  36. Walldius G, Jungner I, Holme I, et al.  High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study) (a prospective study). Lancet. 2001;358:2026–2033
  37. Buchwald H, Boen JR, Nguyen PA, et al.  Plasma lipids and cardiovascular risk (a POSCH report). Atherosclerosis. 2001;154:221–227
  38. Kannel WB, Wilson PW. Efficacy of lipid profiles in prediction of coronary disease. Am Heart J. 1992;124:768–774
  39. Grover SA, Palmer CS, Coupal L. Serum lipid screening to identify high-risk individuals for coronary death (the results of the Lipid Research Clinics Prevalence cohort). Arch Intern Med. 1994;154:679–684
  40. Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease (predicting risks by levels and ratios). Ann Intern Med. 1994;121:654–657
  41. Jones P, Kafonek S, Laurora I, et al.  Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES Study). Am J Cardiol. 1998;81:582–587
  42. Crouse JR, Frohlich J, Ose L, et al.  Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. Am J Cardiol. 1999;83:1476–1477
  43. Davidson M, Ma P, Stein EA, et al.  Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol. 2002;89:268–275
  44. Paoletti R, Fahmy M, Mahla G, et al.  Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients (a randomized, double-blind study). J Cardiovasc Risk. 2001;8:383–390
  45. Stein E, Strutt KL, Miller E, et al.  ZD4522 is superior to atorvastatin in the treatment of patients with heterozygous familial hypercholesterolemia. J Am Coll Cardiol. 2001;37(A Suppl):292A
  46. Smilde TJ, van Wissen S, Wollersheim H, et al.  Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP) (a prospective, randomised, double-blind trial). Lancet. 2001;357:577–581
  47. Rubins HB, Robins SJ, Collins D, et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410–418
  48. Robins SJ, Collins D, Wittes JT, et al.  Relation of gemfibrozil treatment and lipid levels with major coronary events (VA-HIT: a randomized controlled trial). JAMA. 2001;285:1585–1591
  49. Kinosian B, Glick H, Preiss L, et al.  Cholesterol and coronary heart disease (predicting risks in men by changes in levels and ratios). J Invest Med. 1995;43:443–450

PII: S0002-8703(02)94701-0

doi: 10.1016/S0002-8703(02)94701-0

American Heart Journal
Volume 146, Issue 2 , Pages 227-233 , August 2003

Article Tools

* Image Usage & Resolution